|
1
|
Smith WL, DeWitt DL and Garavito RM:
Cyclooxygenases: Structural, cellular, and molecular biology. Annu
Rev Biochem. 69:145–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang D and Dubois RN: Eicosanoids and
cancer. Nat Rev Cancer. 10:181–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao Y and Prescott SM: Many actions of
cyclooxygenase-2 in cellular dynamics and in cancer. J Cell
Physiol. 190:279–286. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zha S, Yegnasubramanian V, Nelson WG,
Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: Progress and
perspective. Cancer Lett. 215:1–20. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Subbaramaiah K and Dannenberg AJ:
Cyclooxygenase 2: A molecular target for cancer prevention and
treatment. Trends Pharmacol Sci. 24:96–102. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bernard MP, Bancos S, Sime PJ and Phipps
RP: Targeting cyclooxygenase-2 in hematological malignancies:
Rationale and promise. Curr Pharm Des. 14:2051–2060. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chien MH, Ku CC, Johansson G, Chen MW,
Hsiao M, Su JL, Inoue H, Hua KT, Wei LH and Kuo ML: Vascular
endothelial growth factor-C (VEGF-C) promotes angiogenesis by
induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1
pathway. Carcinogenesis. 30:2005–2013. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng J, Chen S, Jiang L, You Y, Wu D and
Zhou Y: Functional genetic variations of cyclooxygenase-2 and
susceptibility to acute myeloid leukemia in a Chinese population.
Eur J Haematol. 87:486–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Santos FP, Bueso-Ramos CE and Ravandi F:
Acute erythroleukemia: Diagnosis and management. Expert Rev
Hematol. 3:705–718. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakanishi Y, Kamijo R, Takizawa K, Hatori
M and Nagumo M: Inhibitors of cyclooxygenase-2 (COX-2) suppressed
the proliferation and differentiation of human leukaemia cell
lines. Eur J Cancer. 37:1570–1578. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Subhashini J, Mahipal SV and Reddanna P:
Anti-proliferative and apoptotic effects of celecoxib on human
chronic myeloid leukemia in vitro. Cancer Lett. 224:31–43. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cervi D, Klement G, Stempak D, Baruchel S,
Koki A and Ben-David Y: Targeting cyclooxygenase-2 reduces overt
toxicity toward low-dose vinblastine and extends survival of
juvenile mice with Friend disease. Clin Cancer Res. 11:712–719.
2005.PubMed/NCBI
|
|
13
|
Bonesi M, Loizzo MR, Conforti F,
Passalacqua NG, Saab A, Menichini F and Tundis R: Berberis
aetnensis and B. libanotica: A comparative study on the chemical
composition, inhibitory effect on key enzymes linked to Alzheimer’s
disease and antioxidant activity. J Pharm Pharmacol. 65:1726–1735.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
El Beyrouthy M, Arnold N,
Delelis-Dusollier A and Dupont F: Plants used as remedies
antirheumatic and antineuralgic in the traditional medicine of
Lebanon. J Ethnopharmacol. 120:315–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Imanshahidi M and Hosseinzadeh H:
Pharmacological and therapeutic effects of Berberis vulgaris and
its active constituent, berberine. Phytother Res. 22:999–1012.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zovko Koncić M, Kremer D, Karlović K and
Kosalec I: Evaluation of antioxidant activities and phenolic
content of Berberis vulgaris L. and Berberis croatica Horvat. Food
Chem Toxicol. 48:2176–2180. 2010. View Article : Google Scholar
|
|
17
|
Kim S, Choi JH, Kim JB, Nam SJ, Yang JH,
Kim JH and Lee JE: Berberine suppresses TNF-alpha-induced MMP-9 and
cell invasion through inhibition of AP-1 activity in MDA-MB-231
human breast cancer cells. Molecules. 13:2975–2985. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Singh J and Kakkar P: Antihyperglycemic
and antioxidant effect of Berberis aristata root extract and its
role in regulating carbohydrate metabolism in diabetic rats. J
Ethnopharmacol. 123:22–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roberts MF and Wink M: Alkaloids:
Biochemistry, Ecology, and Medicinal applications. Springer; New
York, London: 1998, View Article : Google Scholar
|
|
20
|
Aniszewski T: Alkaloids-Secrets of Life:
Alkaloid Chemistry, Biological Significance, Applications and
Ecological Role. Elsevier; Amsterdam, Oxford: 2007
|
|
21
|
Huang M, Gao H, Chen Y, Zhu H, Cai Y,
Zhang X, Miao Z, Jiang H, Zhang J, Shen H, et al: Chimmitecan, a
novel 9-substituted camptothecin, with improved anticancer
pharmacologic profiles in vitro and in vivo. Clin Cancer Res.
13:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li W, Shao Y, Hu L, Zhang X, Chen Y, Tong
L, Li C, Shen X and Ding J: BM6, a new semi-synthetic vinca
alkaloid, exhibits its potent in vivo anti-tumor activities via its
high binding affinity for tubulin and improved pharmacokinetic
profiles. Cancer Biol Ther. 6:787–794. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singh T, Vaid M, Katiyar N, Sharma S and
Katiyar SK: Berberine, an isoquinoline alkaloid, inhibits melanoma
cancer cell migration by reducing the expressions of
cyclooxygenase-2, prostaglandin E2 and prostaglandin
E2 receptors. Carcinogenesis. 32:86–92. 2011. View Article : Google Scholar
|
|
24
|
Ho YT, Yang JS, Lu CC, Chiang JH, Li TC,
Lin JJ, Lai KC, Liao CL, Lin JG and Chung JG: Berberine inhibits
human tongue squamous carcinoma cancer tumor growth in a murine
xenograft model. Phytomedicine. 16:887–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Refaat A, Abdelhamed S, Yagita H, Inoue H,
Yokoyama S, Hayakawa Y and Saiki I: Berberine enhances tumor
necrosis factor-related apoptosis-inducing ligand-mediated
apoptosis in breast cancer. Oncol Lett. 6:840–844. 2013.PubMed/NCBI
|
|
26
|
Liu B, Wang G, Yang J, Pan X, Yang Z and
Zang L: Berberine inhibits human hepatoma cell invasion without
cytotoxicity in healthy hepatocytes. PLoS One. 6:e214162011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Peng PL, Hsieh YS, Wang CJ, Hsu JL and
Chou FP: Inhibitory effect of berberine on the invasion of human
lung cancer cells via decreased productions of
urokinase-plasminogen activator and matrix metalloproteinase-2.
Toxicol Appl Pharmacol. 214:8–15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Esseily F, El-Ezzy M, Gali-Muhtasib H,
Safi S, Esseily J, Diab-Assaf M, Lampronti I and Saab A: The
ethanol fraction from the stem of Berberis libanotica inhibits the
viability of adult T cell leukemia. Minerva Biotecnol. 24:129–133.
2012.
|
|
29
|
El-Merahbi R, Liu YN, Eid A, Daoud G,
Hosry L, Monzer A, Mouhieddine TH, Hamade A, Najjar F and
Abou-Kheir W: Berberis libanotica Ehrenb extract shows
anti-neoplastic effects on prostate cancer stem/progenitor cells.
PLoS One. 9:e1124532014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gritsanapan W and Mangmeesri P:
Standardized Senna alata leaf extract. J Health Res. 23:59–64.
2009.
|
|
31
|
Corbiere C, Liagre B, Terro F and
Beneytout JL: Induction of antiproliferative effect by diosgenin
through activation of p53, release of apoptosis-inducing factor
(AIF) and modulation of caspase-3 activity in different human
cancer cells. Cell Res. 14:188–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Smiley ST, Reers M, Mottola-Hartshorn C,
Lin M, Chen A, Smith TW, Steele GD Jr and Chen LB: Intracellular
heterogeneity in mitochondrial membrane potentials revealed by a
J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA.
88:3671–3675. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lepage C, Léger DY, Bertrand J, Martin F,
Beneytout JL and Liagre B: Diosgenin induces death receptor-5
through activation of p38 pathway and promotes TRAIL-induced
apoptosis in colon cancer cells. Cancer Lett. 301:193–202. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leger DY, Liagre B and Beneytout JL: Role
of MAPKs and NF-kappaB in diosgenin-induced megakaryocytic
differentiation and subsequent apoptosis in HEL cells. Int J Oncol.
28:201–207. 2006.
|
|
35
|
Bertrand J, Liagre B, Ghezali L, Beneytout
JL and Leger DY: Cyclooxygenase-2 positively regulates Akt
signalling and enhances survival of erythroleukemia cells exposed
to anticancer agents. Apoptosis. 18:836–850. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ghezali L, Leger DY, Limami Y, Cook-Moreau
J, Beneytout JL and Liagre B: Cyclopamine and jervine induce COX-2
overexpression in human erythroleukemia cells but only cyclopamine
has a pro-apoptotic effect. Exp Cell Res. 319:1043–1053. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsujii M and DuBois RN: Alterations in
cellular adhesion and apoptosis in epithelial cells overexpressing
prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dannenberg AJ, Altorki NK, Boyle JO, Dang
C, Howe LR, Weksler BB and Subbaramaiah K: Cyclo-oxygenase 2: A
pharmacological target for the prevention of cancer. Lancet Oncol.
2:544–551. 2001. View Article : Google Scholar
|
|
39
|
Fürstenberger G, Krieg P, Müller-Decker K
and Habenicht AJ: What are cyclooxygenases and lipoxygenases doing
in the driver’s seat of carcinogenesis? Int J Cancer.
119:2247–2254. 2006. View Article : Google Scholar
|
|
40
|
Ryan EP, Pollock SJ, Kaur K, Felgar RE,
Bernstein SH, Chiorazzi N and Phipps RP: Constitutive and
activation-inducible cyclooxygenase-2 expression enhances survival
of chronic lymphocytic leukemia B cells. Clin Immunol. 120:76–90.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zamzami N, Susin SA, Marchetti P, Hirsch
T, Gómez-Monterrey I, Castedo M and Kroemer G: Mitochondrial
control of nuclear apoptosis. J Exp Med. 183:1533–1544. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Green D and Kroemer G: The central
executioners of apoptosis: Caspases or mitochondria? Trends Cell
Biol. 8:267–271. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu X, Kim CN, Yang J, Jemmerson R and
Wang X: Induction of apoptotic program in cell-free extracts:
Requirement for dATP and cytochrome c. Cell. 86:147–157. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Salvesen GS and Dixit VM: Caspases:
Intracellular signaling by proteolysis. Cell. 91:443–446. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
D’Amours D, Desnoyers S, D’Silva I and
Poirier GG: Poly(ADP-ribosyl)ation reactions in the regulation of
nuclear functions. Biochem J. 342:249–268. 1999. View Article : Google Scholar
|
|
47
|
Nicholson DW: Caspase structure,
proteolytic substrates, and function during apoptotic cell death.
Cell Death Differ. 6:1028–1042. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Giri DK and Aggarwal BB: Constitutive
activation of NF-kappaB causes resistance to apoptosis in human
cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor
necrosis factor and reactive oxygen intermediates. J Biol Chem.
273:14008–14014. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang D and Dubois RN: The role of COX-2 in
intestinal inflammation and colorectal cancer. Oncogene.
29:781–788. 2010. View Article : Google Scholar
|
|
50
|
Limami Y, Pinon A, Leger DY, Mousseau Y,
Cook-Moreau J, Beneytout JL, Delage C, Liagre B and Simon A: HT-29
colorectal cancer cells undergoing apoptosis overexpress COX-2 to
delay ursolic acid-induced cell death. Biochimie. 93:749–757. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kirschenbaum A, Liu X, Yao S and Levine
AC: The role of cyclo-oxygenase-2 in prostate cancer. Urology.
58(Suppl 1): 127–131. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lee KS, Lee HJ, Ahn KS and Kim SH, Nam D,
Kim DK, Choi DY, Ahn KS, Lu J and Kim SH:
Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II
induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett.
280:93–100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Limami Y, Pinon A, Leger DY, Pinault E,
Delage C, Beneytout JL, Simon A and Liagre B: The
P2Y2/Src/p38/COX-2 pathway is involved in the resistance to ursolic
acid-induced apoptosis in colorectal and prostate cancer cells.
Biochimie. 94:1754–1763. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen X, Thakkar H, Tyan F, Gim S, Robinson
H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N and Srivastava RK:
Constitutively active Akt is an important regulator of TRAIL
sensitivity in prostate cancer. Oncogene. 20:6073–6083. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Madrid LV, Mayo MW, Reuther JY and Baldwin
AS Jr: Akt stimulates the transactivation potential of the RelA/p65
Subunit of NF-kappa B through utilization of the Ikappa B kinase
and activation of the mitogen-activated protein kinase p38. J Biol
Chem. 276:18934–18940. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ahn KS, Sethi G and Aggarwal BB: Nuclear
factor-kappa B: From clone to clinic. Curr Mol Med. 7:619–637.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fu L, Chen W, Guo W, Wang J, Tian Y, Shi
D, Zhang X, Qiu H, Xiao X, Kang T, et al: Berberine targets
AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and cytochrome-c/caspase
signaling to suppress human cancer cell growth. PLoS One.
8:e692402013. View Article : Google Scholar
|
|
59
|
Muralimanoharan SB, Kunnumakkara AB,
Shylesh B, Kulkarni KH, Haiyan X, Ming H, Aggarwal BB, Rita G and
Kumar AP: Butanol fraction containing berberine or related compound
from nexrutine inhibits NFkappaB signaling and induces apoptosis in
prostate cancer cells. Prostate. 69:494–504. 2009. View Article : Google Scholar :
|
|
60
|
Goto H, Kariya R, Shimamoto M, Kudo E,
Taura M, Katano H and Okada S: Antitumor effect of berberine
against primary effusion lymphoma via inhibition of NF-κB pathway.
Cancer Sci. 103:775–781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Mencher SK and Wang LG: Promiscuous drugs
compared to selective drugs (promiscuity can be a virtue). BMC Clin
Pharmacol. 5:32005. View Article : Google Scholar : PubMed/NCBI
|
